单份非血缘脐血移植治疗高危/难治儿童AML 160例分析
该回顾性研究分析了2008至2018年接受单份非血缘脐血移植(UCBT)的160例高危/难治儿童急性髓系白血病(AML)患者。全部采用清髓性预处理和CsA联合MMF预防GVHD。结果显示5年总生存率72.2%,无病生存率71.7%,CR1期移植者5年OS达79.9%,结论认为UCBT安全有效,CR1期移植有利于改善预后。
要点
- UCBT后42天中性粒细胞累积植入率95.0%,120天血小板植入率85.5%。
- 5年累积复发率13.8%,5年OS率72.2%,DFS率71.7%。
- CR1期移植者5年OS率79.9%,优于CR2期和未缓解患者。
核心结论
- UCBT是治愈高危/难治儿童AML安全、有效的治疗方法。
- 第1次完全缓解期进行UCBT有利于改善预后。
研究设计与样本
- 回顾性分析2008年6月至2018年12月接受单份UCBT的160例高危/难治AML患儿(不含急性早幼粒细胞白血病)。
- 全部采用清髓性预处理方案,应用环孢素A联合短程霉酚酸酯预防GVHD。
主要发现
- 移植后42天中性粒细胞累积植入率95.0%(95%CI 90.0%~97.5%),中位植入时间16天(范围11~38天)。
- 移植后120天血小板累积植入率85.5%(95%CI 83.3%~93.4%),中位植入时间35天(范围13~158天)。
- Ⅱ~Ⅳ度急性GVHD发生率37.3%(95%CI 29.3%~45.2%),Ⅲ~Ⅳ度27.3%(95%CI 20.0%~35.0%),慢性GVHD 22.4%(95%CI 15.5%~28.7%)。
- 移植后360天TRM为13.1%(95%CI 8.4%~18.9%),5年累积复发率13.8%(95%CI 8.5%~20.3%)。
- 5年DFS率71.7%(95%CI 62.7%~77.8%),OS率72.2%(95%CI 64.1%~78.7%),GRFS率56.1%(95%CI 46.1%~64.9%)。
关键数值与推荐
- CR1组(95例)、CR2组(28例)、NR组(37例)5年累积复发率分别为5.3%(95%CI 1.9%~11.1%)、19.9%(95%CI 6.9%~37.7%)、30.9%(95%CI 14.3%~49.2%)(P=0.001)。
- CR1组、CR2组、NR组5年OS率分别为79.9%(95%CI 70.3%~86.7%)、71.1%(95%CI 50.4%~84.4%)、52.9%(95%CI 33.0%~69.3%)(χ²=7.552,P=0.020)。
临床怎么用
- 对高危/难治儿童AML,单份UCBT可作为安全有效的移植选择。
- 应尽可能在CR1期进行UCBT以改善生存预后。
局限性
- 本研究为单中心回顾性分析,证据等级有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To retrospectively analyze the clinical outcomes of single unrelated cord blood transplantation (UCBT) in children with high risk and refractory acute myeloid leukemia (AML) . Methods: Between June 2008 and December 2018, a total of 160 consecutive pediatric patients with AML received single UCBT (excluding acute promyelocytic leukemia) . Myeloablative conditioning (MAC) regimen were applied. All patients received a combination of cyclosporine A (CsA) and mycophenolate mofetil (MMF) for the prophylaxis of graft -versus- host disease (GVHD) . Results: The cumulative incidence of neutrophil cells engraftment at day +42 and platelet recovery at day +120 was 95.0% (95% CI 90.0%-97.5%) at a median of 16 days after transplantation (range, 11-38 days) and 85.5% (95%CI 83.3%-93.4%) with a median time to recovery of 35 days (range, 13-158) , respectively. Incidence of grades Ⅱ-Ⅳ and Ⅲ-Ⅳ acute GVHD and chronic GVHD were 37.3% (95%CI 29.3%-45.2%) , 27.3% (95%CI 20.0%-35.0%) and 22.4% (95%CI 15.5%-28.7%) , respectively. The transplant-related mortality (TRM) at 360 day was 13.1% (95%CI 8.4%-18.9%) . The 5-year cumulative incidence of relapse was 13.8% (95%CI 8.5%-20.3%) . The 5-year disease-free survival (DFS) and overall survival (OS) were 71.7% (95%CI 62.7%-77.8%) and 72.2% (95%CI 64.1%-78.7%) , respectively. The 5-year GVHD and relapse free survival (GRFS) was 56.1% (95%CI 46.1%-64.9%) . The 5-year cumulative recurrence rates of CR1, CR2, and NR groups were 5.3%, 19.9%, and 30.9% (P=0.001) , and the 5-year OS rates were 79.9% (95%CI 70.3%-86.7%) , 71.1% (95%CI 50.4%-84.4%) and 52.9% (95%CI 33.0%-69.3%) (χ(2)=7.552, P=0.020) , respectively. Conclusions: For pediatric patients with high risk and refractory AML, UCBT is a safe and effective treatment option, and it is favorable to improve the survival rate in CR1 stage. 目的: 探讨单份非血缘脐血干细胞移植(UCBT)治疗高危/难治儿童急性髓系白血病(AML)的疗效。 方法: 对2008年6月至2018年12月期间接受UCBT的160例高危/难治AML(不含急性早幼粒细胞白血病)患儿进行回顾性分析。全部病例均采用清髓性预处理方案,应用环孢素A(CsA)联合短程霉酚酸酯(MMF)预防移植物抗宿主病(GVHD)。 结果: 160例AML患儿中男103例、女57例,中位年龄7(1~14)岁,中位体重23(8~77)kg。移植后42 d中性粒细胞累积植入率为95.0%(95%CI 90.0%~97.5%),移植后120 d血小板累积植入率为85.5%(95%CI 83.3%~93.4%),中性粒细胞、血小板植入中位时间分别为移植后16(11~38)d、35(13~158)d。Ⅱ~Ⅳ、Ⅲ~Ⅳ度急性GVHD发生率分别为37.3%(95%CI 29.3%~45.2%)、27.3%(95%CI 20.0%~35.0%),慢性GVHD发生率为22.4%(95%CI 15.5%~28.7%)。可评估的移植后360 d移植相关死亡率(TRM)为13.1%(95%CI 8.4%~18.9%)。移植后5年累积复发率为13.8%(95%CI 8.5%~20.3%),无病生存(DFS)率为71.7%(95%CI 62.7%~77.8%)、总生存(OS)率为72.2%(95%CI 64.1%~78.7%),无GVHD无复发生存(GRFS)率为56.1%(95%CI 46.1%~64.9%)。移植前处于第1次完全缓解(CR1)期(95例)、第2次完全缓解(CR2)期(28例)、未缓解患者(37例)的移植后5年累积复发率分别为5.3%(95%CI 1.9%~11.1%)、19.9%(95%CI 6.9%~37.7%)、30.9%(95%CI 14.3%~49.2%)(P=0.001),移植后5年OS率分别为79.9%(95%CI 70.3%~86.7%)、71.1%(95%CI 50.4%~84.4%)、52.9%(95%CI 33.0%~69.3%)(χ(2)=7.552,P=0.020)。 结论: UCBT是治愈高危/难治儿童AML安全、有效的治疗方法。第1次完全缓解期进行UCBT有利于改善预后。.
引用
- Chen EL, Liu HL, Geng LQ, et al. [Unrelated cord blood stem cell transplantation for high-risk/refractory childhood acute myeloid leukemia: a clinical analysis of 160 cases]. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 34455741. doi:10.3760/cma.j.issn.0253-2727.2021.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。